Endocrine-Sensitive Disease Rate in Postmenopausal Patients With ER-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
JAMA Oncol 2024 Jan 18;[EPub Ahead of Print], CX Ma, VJ Suman, S Sanati, K Vij, M Anurag, AM Leitch, GW Unzeitig, J Hoog, A Fernandez-Martinez, C Fan, RA Gibbs, MA Watson, TJ Dockter, O Hahn, JM Guenther, A Caudle, E Crouch, A Tiersten, M Mita, W Razaq, TJ Hieken, Y Wang, MF Rimawi, A Weiss, EP Winer, KK Hunt, CM Perou, MJ Ellis, AH Partridge, LA CareyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.